Table 2.
Number of participants (and percentages and 95% CIs) previously encountering (1) each number of possible terms and (2) each specific term
| Screening information | Total | Number of terms previously encountered: n, %, 95 % CIs | |||||||
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | ||
| Breast | n (%) | 583 (59.1) | 73 (7.4) | 76 (7.7) | 53 (5.4) | 41 (4.2) | 28 (2.8) | 9 (0.9) | 124 (12.6) |
| n=987 | 95% CI | 56.0 to 62.1 | 5.9 to 9.2 | 6.2 to 9.5 | 4.1 to 6.9 | 3.0 to 5.5 | 1.9 to 4.0 | 0.5 to 1.7 | 10.6 to 14.7 |
| Prostate | n (%) | 512 (56.8) | 64 (7.1) | 101 (11.2) | 47 (5.2) | 37 (4.1) | 19 (2.1) | 12 (1.3) | 109 (12.1) |
| n=901 | 95% CI | 53.6 to 60.0 | 5.6 to 8.9 | 9.3 to 13.4 | 3.9 to 6.8 | 3.0 to 5.6 | 1.3 to 3.2 | 0.7 to 2.2 | 10.1 to 14.3 |
| Total | n (%) | 1095 (58.0) | 137 (7.3) | 177 (9.4) | 100 (5.3) | 78 (4.1) | 47 (2.5) | 21 (1.1) | 233 (12.3) |
| n=1888 | 95% CI | 55.8 to 60.2 | 6.2 to 8.5 | 8.1 to 10.8 | 4.4 to 6.4 | 3.3 to 4.1 | 1.9 to 3.3 | 0.7 to 1.7 | 10.9 to 13.9 |
| Screening information | Total | ‘Which of the following term or terms had you heard of before?’: n, %, 95 % CIs | |||||||
| Not sure | Overdiagnosis | Overdetection | Unnecessary diagnosis | Overtreatment | Unnecessary treatment | False positive diagnosis | False positive test result | ||
| Breast | n (%) | 7 (0.7) | 215 (21.8) | 163 (16.5) | 214 (21.7) | 225 (22.8) | 280 (28.4) | 243 (24.6) | 270 (27.4) |
| n=987 | 95% CI | 0.3 to 1.4 | 19.3 to 24.4 | 14.3 to 18.9 | 19.2 to 24.3 | 20.3 to 25.5 | 25.6 to 31.2 | 22.0 to 27.4 | 24.6 to 30.2 |
| Prostate | n (%) | 14 (1.6) | 196 (21.8) | 137 (15.2) | 216 (24.0) | 186 (20.6) | 253 (28.1) | 232 (25.7) | 265 (29.4) |
| n=901 | 95% CI | 0.9 to 2.5 | 19.2 to 24.5 | 13.0 to 17.7 | 21.3 to 26.8 | 18.1 to 23.4 | 25.2 to 31.1 | 23.0 to 28.7 | 26.5 to 32.4 |
| Total | n (%) | 21 (1.1) | 411 (21.8) | 300 (15.9) | 430 (22.8) | 411 (21.8) | 533 (28.2) | 475 (25.2) | 535 (28.3) |
| n=1888 | 95% CI | 0.7 to 1.7 | 20.0 to 23.7 | 14.3 to 17.6 | 20.9 to 24.7 | 20.0 to 23.7 | 26.2 to 30.3 | 23.2 to 27.2 | 26.3 to 30.4 |
Participants receiving overdiagnosis information based on the Breast Screening Programme or the Prostate Cancer Risk Management Programme were analysed separately.